| 杨玲 田云 杨浩 张琳 金蕊.康莱特配伍吉非替尼治疗对晚期非小细胞肺癌患者免疫功能和生活质量的影响[J].现代生物医学进展英文版,2016,16(19):3728-3730. |
| 康莱特配伍吉非替尼治疗对晚期非小细胞肺癌患者免疫功能和生活质量的影响 |
| Influence of Kanglaite Combined with Gefitinib on Immune Function andQuality of Life of Patients with Advanced Non-small Cell Lung Cancer |
| |
| DOI： |
| 中文关键词: 康莱特 吉非替尼 非小细胞肺癌 生活质量 |
| 英文关键词: Kanglaite Gefitinib Non-small cell lung cancer Quality of life |
| 基金项目: |
|
| Hits: 642 |
| Download times: 0 |
| 中文摘要: |
| 目的：评估康莱特（KLT）配伍吉非替尼治疗对晚期非小细胞肺癌（NSCLC）的免疫功能和生活质量的影响。方法：选取我院
2013 年1月－2014 年7 月诊治的晚期NSCLC 患者64 例并随机分为两组各32 例。对照组给予吉非替尼口服，试验组在对照组
基础上加KLT 静脉滴注。观察两组T 淋巴细胞亚群CD3+、CD4+、CD8+、CD4+/ CD8+表达情况及自然杀伤（NK）细胞活性；采用生
活质量量表（QLQ-CCC）和卡式功能状态量表（KPS）对生活质量及功能状态进行评估。结果：试验组T 淋巴细胞亚群CD4+、
CD4+/CD8+表达率及NK 细胞活性高于对照组（P<0.05），且其治疗前后的差值低于对照组（P<0.05）；试验组躯体、心理、社会、
QLQ-CCC 总分及KPS 得分均高于对照组，且其治疗前后的差值均高于对照组（P<0.05）。结论：KLT 配伍吉非替尼治疗晚期
NSCLC 可减少吉非替尼对免疫功能的损害，提高患者的生活质量。 |
| 英文摘要: |
| Objective:To evaluate the influence of kanglaite(KLT) combined with gefitinib on immune function and quality of life
of patients with advanced non-small cell lung cancer (NSCLC).Methods:A total of 64 patients with advanced NSCLC,who were treated
in Shanxi Tumor Hospital from January 2013 to July 2014,were selected and randomly divided into two groups with 32 patients in each
group. The control group was treated with oral gefitinib, while the experimental group was added KLT intravenous drip on the basis of
control group's therapy. The expression of CD3+, CD4+, CD8+, CD4+/CD8+ of T lymphocyte subsets and the natural killer(NK) cell activity
in the two groups were observed. The quality of life and performance status were assessed by Chinese cancer patients receiving chemobiotherapy
(QLQ-CCC) and karnofsky performance status (KPS) scale.Results:The expression rates of CD4+, CD4+/CD8+ of T lymphocyte
subsets and NK cell activity in the experimental group were higher than those in the control group (P<0.05), and the minus values of
before and after treatment were lower than those in the control group (P<0.05). The physical, psychology,social and QLQ-CCC total
scores and KPS score in the experimental group were higher than those in the control group, and the minus values of before and after
treatment were higher than those in the control group (P<0.05).Conclusion:KLT combined with gefitinib can reduce the damage of gefitinib
to immune function and improve the life of quality of patients with advanced NSCLC. |
|
View Full Text
View/Add Comment Download reader |
| Close |
